Cargando…

Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease

BACKGROUND: Lipoprotein (a) [Lp(a)] is an independent risk factor for coronary artery disease (CAD). Recent studies have indicated that statins tend to increase Lp(a) levels by 10–20%. However, the association of statin-mediated increases in Lp(a) levels with CAD has not been determined. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Lijun, Fang, Yangliang, Gao, Beibei, Jin, Xiangbo, Zheng, Jiamin, He, Ying, Huang, Jinyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644478/ https://www.ncbi.nlm.nih.gov/pubmed/36348286 http://dx.doi.org/10.1186/s12872-022-02932-y

Ejemplares similares

Correction: Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease
por: Zhu, Lijun, et al.
Publicado: (2022)

Impact of epicardial adipose tissue volume on hemodynamically significant coronary artery disease in Chinese patients with known or suspected coronary artery disease
por: Jin, Xiangbo, et al.
Publicado: (2023)

The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels
por: Zhu, Lijun, et al.
Publicado: (2022)

Statins and Lp(a) – the plot thickens
por: Enkhmaa, Byambaa, et al.
Publicado: (2019)

Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
por: Pechlivanis, Sonali, et al.
Publicado: (2020)

Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
por: Kostner, Karam M., et al.
Publicado: (2022)

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India
por: Sharma, Krishna K, et al.
Publicado: (2009)

Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults
por: Musich, Shirley, et al.
Publicado: (2019)

Independent association of Lp(a) with platelet reactivity in subjects without statins or antiplatelet agents
por: Liu, Huixing, et al.
Publicado: (2022)

Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions
por: Al Hageh, Cynthia, et al.
Publicado: (2023)

Role of Statins in Coronary Artery Disease
por: Lim, Sang Yup
Publicado: (2013)

Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
por: Enkhmaa, Byambaa, et al.
Publicado: (2020)

Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
por: Zhu, Ling, et al.
Publicado: (2020)

Statins for primary cardiovascular prevention in the elderly
por: Pedro-Botet, Juan, et al.
Publicado: (2015)

Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013)

Editorial Lp(a) – the underestimated cardiovascular risk factor
por: Mellwig, Klaus-Peter
Publicado: (2017)

Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients
por: Schonberger, Robert B., et al.
Publicado: (2020)

Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases
por: Farina, Juan M., et al.
Publicado: (2023)

Statins for the Primary Prevention of Coronary Heart Disease
por: Li, Min, et al.
Publicado: (2019)

The effect of apolipoprotein E gene polymorphism and Lp(a) levels on coronary artery disease with atrial fibrillation
por: Li, Yong, et al.
Publicado: (2022)

Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population
por: Cai, Anping, et al.
Publicado: (2015)

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
por: Thalmann, Inna, et al.
Publicado: (2023)

Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi‐Ethnic Study of Atherosclerosis)
por: Miedema, Michael D., et al.
Publicado: (2018)

Practice setting and secondary prevention of coronary artery disease
por: Jankowski, Piotr, et al.
Publicado: (2017)

Room for standardisation: the secondary prevention of coronary artery disease
por: Bahl, Rahul
Publicado: (2021)

Statin therapy in the primary prevention of early atrial fibrillation after coronary artery bypass grafting
por: Bockeria, O.L., et al.
Publicado: (2016)

Guideline-Based Statin Eligibility, Coronary Artery Stenosis and Cardiovascular Events in Patients with Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial
por: Pursnani, Amit, et al.
Publicado: (2020)

Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins
por: Morales-Villegas, Enrique C., et al.
Publicado: (2011)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease
por: Ma, Sha, et al.
Publicado: (2022)

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians – A population with the highest risk of premature coronary artery disease & diabetes
por: Enas, Enas A., et al.
Publicado: (2013)

Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials
por: Zhu, Houyong, et al.
Publicado: (2023)

Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016
por: Yao, Xiaoxi, et al.
Publicado: (2020)

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
por: Zhou, Xiao-hong, et al.
Publicado: (2020)

Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease
por: Ishii, Junnichi, et al.
Publicado: (2022)

Investigating potential mediator between statin and coronary artery calcification
por: Lee, Donghun, et al.
Publicado: (2018)

Effect of Statins on the Inflammatory Markers in Patients with Coronary Artery Disease
por: Premnath, Sujatha Mahadevarao, et al.
Publicado: (2023)

Dual antiplatelet therapy for secondary prevention of coronary artery disease
por: Degrauwe, Sophie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_191uid3g93qokbd5hrli2s9cgv